---
title: "Fagron NV FY 2025 REBITDA rises 10.9% to EUR 192.9 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275705516.md"
datetime: "2026-02-12T06:01:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275705516.md)
  - [en](https://longbridge.com/en/news/275705516.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275705516.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275705516.md) | [繁體中文](https://longbridge.com/zh-HK/news/275705516.md)


# Fagron NV FY 2025 REBITDA rises 10.9% to EUR 192.9 million

Fagron NV reported full year (FY) 2025 results, posting revenue of EUR 952.2 million, a 9.2% increase. REBITDA rose 10.9% to EUR 192.9 million, resulting in a REBITDA margin of 20.3%. Operating cash flow was EUR 155.3 million, with free cash flow up 29.0% to EUR 125.9 million. The company’s leverage ratio decreased to 1.2x, providing financial flexibility for expansion and acquisitions. Earnings per share reached EUR 1.25, a 13.6% increase, with a proposed dividend of EUR 0.40 per share, up 14.3%. During the period, Fagron NV announced 12 acquisitions across regions and segments, and integration of closed acquisitions is progressing as planned. Product availability was above 90%, and procurement and manufacturing savings exceeded targets. EMEA performance was supported by geographical diversification and integration of recent acquisitions, while Latin America—particularly Brazil—benefited from its Brands portfolio and innovation pipeline. North America-Pacific saw continued outsourcing demand and onboarding of new customers, supported by efficiency initiatives. For FY 2026, Fagron NV forecasts mid- to high-single digit organic sales growth and a slightly improving margin. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fagron NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001164257-en) on February 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [NewAmsterdam Pharma Company N.V. (NAMS.US)](https://longbridge.com/en/quote/NAMS.US.md)
- [Pharvaris N.V. (PHVS.US)](https://longbridge.com/en/quote/PHVS.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

- [Iterum Therapeutics Received Notice of Delisting](https://longbridge.com/en/news/281174211.md)
- [InSilico Medicine Strikes Multi-Billion-Dollar AI Drug Discovery Deal With Eli Lilly](https://longbridge.com/en/news/280909399.md)
- [US 10 Year Note Futures Hold Key Support as Macro Crosscurrents Build](https://longbridge.com/en/news/281024783.md)
- [1 reason why April 10 could be huge for Taiwan Semiconductor Manufacturing](https://longbridge.com/en/news/281631198.md)
- [Wealth First Promoters Confirm 74% Stake With No Encumbrance in FY26](https://longbridge.com/en/news/281530653.md)